

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 February 2020 (27.02.2020)



(10) International Publication Number
WO 2020/039025 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/5377 (2006.01)

(21) International Application Number:
PCT/EP2019/072467

(22) International Filing Date:
22 August 2019 (22.08.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18190731.2 24 August 2018 (24.08.2018) EP

(71) Applicants: **BAYER AKTIENGESELLSCHAFT**
[DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Leverkusen
(DE). **BAYER PHARMA AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstr. 178, 13353 Berlin (DE).

(72) Inventors: **PLATZEK, Johannes**; Grottkauer Str. 55,
12621 Berlin (DE). **RUBENBAUER, Philipp**; Zur Holder-
hecke 10a, 64625 Bensheim (DE). **VAN DER HAAS, Hen-
ricus, Nicolaas, Sebastiaan**; Claustum 30, 6515 GK Ni-
jmegen (NL). **HOOGEVEEN, Sonja, Elisabeth**; Irenelaan
30, 5342 EL Oss (NL). **VAN OERS, Matthijs, Cor-
nelis, Maria**; Vondelstraat 111, 6512 BD Nijmegen (NL).
GIELING, Reinerus, Gerardus; De Liende 12, 6441 XJ
Beuningen (NL). **DEKKER, Jeroen, Alexander**; Rem-
brandilaan 131, 6717 NS Ede (NL).

(74) Agent: **BIP PATENTS**; Alfred-Nobel-Str. 10, 40789 Mon-
heim am Rhein NRW (DE).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL]-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE



(I)

(57) Abstract: The present invention covers a method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-[1-methyl-1H-pyrazol-5-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine ("the compound of formula (I)" in the following) as well as intermediate compounds useful in the preparation of the compound of formula (I). The present invention also covers polymorphic form B of the compound of formula (I) with very high purity.

WO 2020/039025 A1